161 related articles for article (PubMed ID: 27020477)
21. HLA-B*51:79 is a novel allele associated with a conserved haplotype.
Perrier P; Leisenbach R; Tourne S; Kennel A; Proust B
Tissue Antigens; 2011 Oct; 78(4):288-9. PubMed ID: 21671889
[TBL] [Abstract][Full Text] [Related]
22. HLA class I (A, B, C) and class II (DRB1, DQA1, DQB1, DPB1) alleles and haplotypes in the Han from southern China.
Trachtenberg E; Vinson M; Hayes E; Hsu YM; Houtchens K; Erlich H; Klitz W; Hsia Y; Hollenbach J
Tissue Antigens; 2007 Dec; 70(6):455-63. PubMed ID: 17900288
[TBL] [Abstract][Full Text] [Related]
23. Expression Analysis of Long Non-coding RNA Lnc-DC in HLA-DRB1*15:01-Negative Patients with Multiple Sclerosis: A Probable Cause for Gender Differences in Multiple Sclerosis Susceptibility?
Bahrami T; Taheri M; Javadi S; Omrani MD; Karimipour M
J Mol Neurosci; 2021 Apr; 71(4):821-825. PubMed ID: 32951137
[TBL] [Abstract][Full Text] [Related]
24. [Correlation of HLA-A, B, DRB1 genes with leukemia].
Du Y; Liang XL; Li Q; Wu WJ; Liu J; Sun LJ; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):285-8. PubMed ID: 23628017
[TBL] [Abstract][Full Text] [Related]
25. Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
Buck D; Andlauer TF; Igl W; Wicklein EM; Mühlau M; Weber F; Köchert K; Pohl C; Arnason B; Comi G; Cook S; Filippi M; Hartung HP; Jeffery D; Kappos L; Barkhof F; Edan G; Freedman MS; Montalbán X; Müller-Myhsok B; Hemmer B;
Mult Scler; 2019 Apr; 25(4):565-573. PubMed ID: 29521573
[TBL] [Abstract][Full Text] [Related]
26. HLA-A, HLA-B and HLA-DRB1 allele and haplotype diversity among volunteer bone marrow donors from Croatia.
Grubic Z; Burek Kamenaric M; Mikulic M; Stingl Jankovic K; Maskalan M; Zunec R
Int J Immunogenet; 2014 Jun; 41(3):211-21. PubMed ID: 24762167
[TBL] [Abstract][Full Text] [Related]
27. Differential methylation at
Maltby VE; Lea RA; Sanders KA; White N; Benton MC; Scott RJ; Lechner-Scott J
Clin Epigenetics; 2017; 9():71. PubMed ID: 28729889
[TBL] [Abstract][Full Text] [Related]
28. Multiple sclerosis: disease modifying therapy and the human leukocyte antigen.
Werneck LC; Lorenzoni PJ; Kay CSK; Scola RH
Arq Neuropsiquiatr; 2018 Oct; 76(10):697-704. PubMed ID: 30427510
[TBL] [Abstract][Full Text] [Related]
29. [Relationship between polymorphism of HLA-A, -B, -DRB1 alleles and susceptibility of children to acquired aplastic anemia].
Lu SY; Xiao LL; Luo M; Zhang BH; Chen C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):120-4. PubMed ID: 22391180
[TBL] [Abstract][Full Text] [Related]
30. Influence of histocompatibility genes on disease susceptibility and treatment response in patients with relapsing-remitting multiple sclerosis treated with interferon β-1a.
Flechter S; Klein T; Pollak L
Neurol Int; 2011 Jun; 3(1):e5. PubMed ID: 21785677
[TBL] [Abstract][Full Text] [Related]
31. Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response.
Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A; Tilea B; Tiu C
CNS Neurol Disord Drug Targets; 2017; 16(1):93-101. PubMed ID: 27306062
[TBL] [Abstract][Full Text] [Related]
32. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
[TBL] [Abstract][Full Text] [Related]
33. Association of HLA-DRB1*1501 tagging rs3135388 gene polymorphism with multiple sclerosis.
Benešová Y; Vašků A; Stourač P; Hladíková M; Fiala A; Bednařík J
J Neuroimmunol; 2013 Feb; 255(1-2):92-6. PubMed ID: 23186557
[TBL] [Abstract][Full Text] [Related]
34. Sensitivity to bee venom antigen phospholipase A2: association with specific HLA class I and class II alleles and haplotypes in beekeepers and allergic patients.
Sánchez-Velasco P; Antón E; Muñoz D; Martínez-Quesada J; Ruíz de Alegría C; López-Hoyos M; García-Martín A; Jiménez I; Alonso ST; Duque S; Suárez A; Jerez J; Leyva-Cobián F
Hum Immunol; 2005 Jul; 66(7):818-25. PubMed ID: 16112029
[TBL] [Abstract][Full Text] [Related]
35. Correlations between HLA-A, HLA-B and HLA-DRB1 allele polymorphisms and childhood susceptibility to acquired aplastic anemia.
Chen C; Lu S; Luo M; Zhang B; Xiao L
Acta Haematol; 2012; 128(1):23-7. PubMed ID: 22572536
[TBL] [Abstract][Full Text] [Related]
36. Frequency of HLA-A, -B and -DRB1 specificities and haplotypic associations in the population of Castilla y León (northwest-central Spain).
Alcoceba M; Marín L; Balanzategui A; Sarasquete ME; Chillón MC; Martín-Jiménez P; Puig N; Santamaría C; Corral R; García-Sanz R; San Miguel JF; González M
Tissue Antigens; 2011 Oct; 78(4):249-55. PubMed ID: 21929573
[TBL] [Abstract][Full Text] [Related]
37. Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general.
Gustavsen MW; Viken MK; Celius EG; Berge T; Mero IL; Berg-Hansen P; Aarseth JH; Myhr KM; Søndergaard HB; Sellebjerg F; Oturai AB; Hillert J; Alfredsson L; Olsson T; Kockum I; Lie BA; Harbo HF
J Neuroimmunol; 2014 Sep; 274(1-2):174-9. PubMed ID: 25037176
[TBL] [Abstract][Full Text] [Related]
38. Smoking affects the interferon beta treatment response in multiple sclerosis.
Petersen ER; Oturai AB; Koch-Henriksen N; Magyari M; Sørensen PS; Sellebjerg F; Søndergaard HB
Neurology; 2018 Feb; 90(7):e593-e600. PubMed ID: 29343473
[TBL] [Abstract][Full Text] [Related]
39. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis.
Zivadinov R; Uxa L; Bratina A; Bosco A; Srinivasaraghavan B; Minagar A; Ukmar M; Benedetto Sy; Zorzon M
Int Rev Neurobiol; 2007; 79():521-35. PubMed ID: 17531857
[TBL] [Abstract][Full Text] [Related]
40. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
Chevalier J; Chamoux C; Hammès F; Chicoye A
PLoS One; 2016; 11(3):e0150703. PubMed ID: 26987055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
